Andreas Argyrides Analyst PerformanceManaging Director, Senior Biotech Analyst at OppenheimerAndreas Argyrides is a stock analyst at Oppenheimer in the healthcare sector, covering 27 publicly traded companies. Over the past year, Andreas Argyrides has issued 33 stock ratings, including strong buy, buy, hold, and sell recommendations. While full access to Andreas Argyrides' proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Andreas Argyrides' coverage history, rating activity, and performance tendencies - helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings58 Last 4 YearsBuy Recommendations80.70% 46 Buy RatingsCompanies Covered27 Unique Companies Ratings Distribution57RatingsDistribution of strong buy, buy, hold, and sell ratings by Andreas Argyrides.RatingPercentageCount Strong Buy3.5%2 ratings Buy77.2%44 ratings Hold15.8%9 ratings Sell3.5%2 ratingsOut of 57 total stock ratings issued by Andreas Argyrides at Oppenheimer, the majority (77.2%) have been Buy recommendations, followed by 15.8% Hold, 3.5% Strong Buy, and 3.5% Sell.Best & Worst CallsBest Call0000.0%MNPRSep 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%KALASep 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ96.3% of companies on NASDAQ26 companiesNYSE3.7% of companies on NYSE1 companyAndreas Argyrides, an analyst at Oppenheimer, currently covers 27 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageHealthcare27 companies100.0%Andreas Argyrides of Oppenheimer specializes in stock coverage within the Healthcare sector.Coverage IndustriesIndustryPercentageBIOTECHNOLOGY21 companies77.8%PHARMACEUTICALS6 companies22.2% About Andreas ArgyridesAndreas Argyrides is an Executive Director and Senior Analyst covering Biotechnology. Prior to joining Oppenheimer, Andreas was Vice President and Senior Analyst covering Biotechnology at Wedbush. Prior to Wedbush, Andreas spent a decade in various roles across the healthcare industry including as healthcare sector specialist and research analyst at a long/short biotech focused hedge fund. Andreas received his BA in History and Economics with honors from New York University.Follow on LinkedIn Andreas Argyrides' Ratings History at Oppenheimer Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsAGENAgenus9/18/2026Initiated Coverage$7.22$40.00Buy$0.0000.00% ROIOCULOcular Therapeutix9/16/2026Reiterated Rating$10.19$23.00Buy$0.0000.00% ROIIRDOpus Genetics9/9/2026Boost Price Target$5.65$16.00Buy$0.0000.00% ROIIRDOpus Genetics9/9/2026Boost Price Target$5.73$20.00Outperform$0.0000.00% ROIIRDOpus Genetics9/9/2026Reiterated Rating$4.34$13.00Buy$0.0000.00% ROIRANIRani Therapeutics8/26/2026Upgrade$0.85Strong-Buy$0.0000.00% ROIRANIRani Therapeutics8/18/2026Initiated Coverage$0.80Buy$0.0000.00% ROIEYPTEyepoint Pharmaceuticals8/18/2026Downgrade$4.87$5.00Neutral$0.0000.00% ROIEYPTEyepoint Pharmaceuticals8/17/2026Reiterated Rating$14.75$5.00Neutral$0.0000.00% ROIEYPTEyepoint Pharmaceuticals8/7/2026Reiterated Rating$12.83$65.00Buy$0.0000.00% ROI Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. OCULOcular Therapeutix8/4/2026Reiterated Rating$8.40$23.00Buy$0.0000.00% ROIIRDOpus Genetics7/6/2026Reiterated Rating$4.33$13.00Buy$0.0000.00% ROIEYPTEyepoint Pharmaceuticals7/1/2026Boost Price Target$14.28$65.00Buy$0.0000.00% ROIOCULOcular Therapeutix6/25/2026Boost Price Target$9.97$23.00Buy$0.0000.00% ROIIRDOpus Genetics6/18/2026Boost Price Target$4.06$13.00Buy$0.0000.00% ROIIRDOpus Genetics6/17/2026Upgrade$4.08Strong-Buy$0.0000.00% ROIIRDOpus Genetics3/16/2026Initiated Coverage$5.03$10.00Outperform$0.0000.00% ROILQDALiquidia3/12/2026Boost Price Target$37.07$19.00Underperform$0.0000.00% ROIGOSSGossamer Bio3/5/2026Lower Price Target$38.60$240.00Outperform$0.0000.00% ROIUTHRUnited Therapeutics2/26/2026Boost Price Target$500.08$600.00Outperform$0.0000.00% ROIMLTXMoonLake Immunotherapeutics2/24/2026Boost Price Target$18.68$35.00Outperform$0.0000.00% ROIEVMNEvommune1/22/2026Initiated Coverage$18.64$42.00Outperform$0.0000.00% ROISVRASavara12/23/2025Set Price Target$6.51$10.00$0.0000.00% ROIDYNDyne Therapeutics12/10/2025Upgrade$18.44$40.00Outperform$0.0000.00% ROIHRMYHarmony Biosciences11/24/2025Reiterated Rating$34.31$62.00Outperform$0.0000.00% ROISVRASavara11/14/2025Boost Price Target$4.33$9.00Outperform$0.0000.00% ROIDYNDyne Therapeutics11/12/2025Lower Price Target$18.86$11.00Market Perform$0.0000.00% ROIKROSKeros Therapeutics11/12/2025Reiterated Rating$17.28$27.00Outperform$0.0000.00% ROIDYNDyne Therapeutics10/10/2025Reiterated Rating$14.68$13.00Market Perform$0.0000.00% ROIDYNDyne Therapeutics10/10/2025Downgrade$14.68$13.00Market Perform$0.0000.00% ROIMNPRMonopar Therapeutics10/2/2025Set Price Target$92.52$115.00Outperform$0.0000.00% ROILRMRLarimar Therapeutics10/2/2025Lower Price Target$4.46$21.00Outperform$0.0000.00% ROIBNTCBenitec Biopharma9/16/2025Reiterated Rating$13.60$29.00Outperform$00.0000.00% ROIKALAKALA BIO9/11/2025Boost Price Target$795.75$1,650.00Outperform$0.0000.00% ROISVRASavara9/8/2025Boost Price Target$3.72$8.00Outperform$0.0000.00% ROIUTHRUnited Therapeutics9/5/2025Boost Price Target$387.63$575.00Outperform$000.0000.00% ROIMNKDMannKind9/5/2025Boost Price Target$5.54$15.00Outperform$0.0000.00% ROIMNPRMonopar Therapeutics9/3/2025Initiated Coverage$33.93$77.00Outperform$000.0000.00% ROIABEOAbeona Therapeutics8/15/2025Boost Price Target$7.25$20.00Outperform$0.0000.00% ROIDYNDyne Therapeutics8/6/2025Lower Price Target$10.47$13.00Outperform$00.0000.00% ROICODE RED: AI Meltdown Imminent? (Ad)After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to trigger the next crash. The research firm Bernstein Research said this AI company has the power to crash the global economy for a decade, the CEO just issued a CODE RED in an internal memo warning employees they're dealing with a critical situation, and another company executive even implied they might need a government bailout. The last time I saw something like this was in 2008 when I predicted a stock market meltdown just three weeks before Lehman went under.See the five simple steps to prepare before it's too lateHRMYHarmony Biosciences6/2/2025Initiated Coverage$34.69$61.00Outperform$00.0000.00% ROIDYNDyne Therapeutics6/2/2025Initiated Coverage$12.04$34.00Outperform$00.0000.00% ROIAQSTAquestive Therapeutics6/2/2025Initiated Coverage$2.71$7.00Outperform$0.0000.00% ROIABEOAbeona Therapeutics6/2/2025Initiated Coverage$6.29$19.00Outperform$0.0000.00% ROIKALAKALA BIO6/2/2025Reiterated Rating$183.80$750.00Outperform$0.0000.00% ROIIFRXInflaRx5/29/2025Lower Price Target$0.83$3.00Outperform$0.0000.00% ROILQDALiquidia5/19/2025Set Price Target$18.88$13.00Underperform$00.0000.00% ROIRANIRani Therapeutics5/16/2025Lower Price Target$0.73$4.00Outperform$0.0000.00% ROIKRROKorro Bio5/13/2025Lower Price Target$16.11$90.00Outperform$00.0000.00% ROIPRQRProQR Therapeutics5/13/2025Lower Price Target$1.59$9.00Outperform$0.0000.00% ROICNTACentessa Pharmaceuticals5/8/2025Initiated Coverage$12.41$6.00Outperform$00.0000.00% ROIIFRXInflaRx5/8/2025Initiated Coverage$1.47$6.00Outperform$0.0000.00% ROIKROSKeros Therapeutics1/16/2025Lower Price Target$10.19$23.00Outperform$00.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageUBS GroupCitigroupBarclaysRoyal Bank Of CanadaMorgan StanleyWells Fargo & CompanyJPMorgan Chase & Co.Jefferies Financial GroupThe Goldman Sachs GroupTD CowenTruist FinancialPiper SandlerDeutsche Bank AktiengesellschaftBMO Capital MarketsMizuho Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
